CMN Weekly (25 April 2025) - Your Weekly CRISPR...
CMN Weekly
Apr. 25, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Laverock Therapeutics
Company Type: Therapeutics
Main focus: Development of gene-silencing platform for the creation of programmable advanced therapies
Company stage: Pre-clinical
Diseases: Regenerative medicine and oncology
Genome-editing tool: Gene editing induced gene silencing (GEiGS) technology
Funding stage: Seed
Location: Stevenage, UK
Website: https://www.laverocktx.com
Pipeline: https://www.laverocktx.com/therapeutics
Partners:
Laverock Therapeutics is a pre-clinical stage company based in Steveage, UK, that is developing a unique gene-silencing platform for the creation of programmable advanced therapies. The company was established in 2021 to commercialise the gene-editing induced gene silencing (GEiGS) technology for human therapeutic applications. The company is currently focusing on two core disease areas – regenerative medicine and oncology.
